Junttila, Melissa R.

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature

Cancer Cells and MetastasisCancer Immunotherapy and Biomarkers

Cited by 2,694

Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy

Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 857

Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

Junttila, M. R., Li, S., & Westermarck, J. (2008) · The FASEB Journal

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 826

CIP2A inhibits PP2A in human malignancies

Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell

Cancer Mechanisms and TherapyProtein Tyrosine Phosphatases

Cited by 677

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway Studies

Cited by 561

Distinct Thresholds Govern Myc's Biological Output In Vivo

Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 456

Translational value of mouse models in oncology drug development

Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine

Animal testing and alternativesCancer Cells and Metastasis

Cited by 293

MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer

Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute

Cancer Mechanisms and TherapyGastric Cancer Management and Outcomes

Cited by 185

Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer

Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., et al. (2015) · Science Translational Medicine

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 182

Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1

Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 130

Harnessing the predictive power of preclinical models for oncology drug development

Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery

Animal testing and alternativesCancer Cells and Metastasis

Cited by 121